平成29年度

巻頭言

平成29年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成30年10月1日の人事異動により）
奥野　清隆（外科学教授 下部消化管部門教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成29年度ライフサイエンス研究所紀要

外科学教室 下部消化管部門（奥野　清隆　教授）

1. Tanaka H, Hazama S, Iida M, Tsunedomi R, Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y, Tomochika S, Tokuhisa Y, Sakamoto K, Suzuki N, Takeda S, Yamamoto S1, Yoshino S, Ueno T, Hamamoto Y, Fujita Y, Tanaka H, Tahara K, Shimizu R, Okuno K, Fujita K, Kuroda M, Nakamura Y, Nagano H.
   miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer.
   Cancer Sci. 108(11):2229-2238, 2017.
2. Shindo Y, Hazama S, Nakamura Y, Inoue Y, Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno T, Takeda S, Yoshino S, Okuno K, Fujita Y, Hamamoto Y, Kawakami Y, Oka M, Nagano H.
   miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer.
   Oncol Lett. 14(2):1355-1362, 2017.
3. Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N.
   Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement.
   Mol Clin Oncol. 7(3):359-366, 2017.
4. Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S.
   Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial). Cancer Chemother Pharmacol . 81(1):65-71,2018.
5. Kawamura J, Sugiura F, Sukegawa Y, Yoshioka Y, Hida JI, Hazama S, Okuno K.
   Cytotoxic T Iymphocyte response to peptide vaccination predicts survival in stageⅢcolorectal cancer.
   Cancer Sci. 109(5):1545-1551,2018.
6. Kawamura J, Sugiura F, Sukegawa Y, Yoshioka Y, Hida JI, Hazama S, Okuno K.
   Multicenter,phase Ⅱ clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage Ⅲ colorectal cancer.
   Oncol Lett. 15(4):4241-4247,2018.
7. 助川 寧、川村 純一郎、奥野 清隆
   担癌マウスにおけるCyclophosphamideと椎茸菌糸体培養培地抽出物(LEM)・霊芝菌糸体培地抽出物(MAK)の併用による延命効果
   癌と化学療法.44(10):896-899 (2017)
8. 奥野清隆
   大腸癌に対するがんペプチドワクチンの開発
   ペプチド医薬品のスクリーニング・安定化・製剤化技術. 448-457 (2017)[画像]
9. 吉岡 康多、所 忠男、牛嶋 北斗、大東 弘治、川村 純一郎、上田 和毅、肥田 仁一、奥野 清隆
   直腸GISTに対して術前メシル酸イマチニブ投与により局所切除術を成し得た1例
   Jpn J Cancer Chemother 44(12):1997-1999,2017.

病理学教室（伊藤　彰彦　教授）

1. Takashima Y, Murakami T, Inoue T, Hagiyama M, Yoneshige A, Nishimura S, Akagi M, Ito A.
   Manifestation of osteoblastic phenotypes in the sarcomatous component of epithelial carcinoma and sarcomatoid carcinoma.
   Tumour Biol. 39(6):1010428317704365,2017.
2. Iino T, Hagiyama M, Furuno T, Ito A, Hosokawa Y.
   Time-Course Statistical Evaluation of Intercellular Adhesion Maturation by Femtosecond Laser Impulse.
   Biophys J. 111(10):2255-2262,2016.
3. Kato T, Mizuguchi N, Ito A
   Candesartan suppresses proteinuria and decrease of nephrin expression but hydralazine does not in hypertensive nephropathy.
   J. Biomed , 2: 57-63,2017.

免疫学教室（宮澤　正顯　教授）

1. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.
   B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
   Clin Cancer Res. 24(11):2653-2664,2018.
2. Fujino M, Sato H, Okamura T, Uda A, Takeda S, Ahmed N, Shichino S, Shiino T, Saito Y, Watanabe S, Sugimoto C, Kuroda MJ, Ato M, Nagai Y, Izumo S, Matsushima K, Miyazawa M, Ansari AA, Villinger F, Mori K.
   Simian Immunodeficiency Virus Targeting of CXCR3+ CD4+ T Cells in Secondary Lymphoid Organs Is Associated with Robust CXCL10 Expression in Monocyte/Macrophage Subsets.
   J Virol.91(13). pii: e00439-17,2017.
3. 報告書
   宮澤 正顯
   細胞内複製制限因子APOBEC3の進化要因としての異種由来レトロウイルス.
   平成24-28年度科学研究費助成事業 新学術領域研究
   ウイルス感染現象における宿主細胞コンピテンシーの分子基盤（領域代表者 永田 恭介）
   研究成果報告書 72-73, 2018.
4. 著書
   宮澤 正顯
   青笹 克之、加藤 光保、菅野 祐幸・編集
   解明 病理学 第３版 病気のメカニズムを解く 第5章　免疫 89-136, 2017.

公衆衛生学教室（伊木　雅之　教授）

1. Iki M, Fujita Y, Kouda K, Yura A, Tachiki T, Tamaki J, Winzenrieth R, Sato Y, Moon JS, Okamoto N, Kurumatani N.
   Hyperglycemia is associated with increased bone mineral density and decreased trabecular bone score in elderly Japanese men: The Fujiwara-kyo osteoporosis risk in men (FORMEN) study.
   Bone. 105:18-25,2017.
2. Tamaki J, Kouda K, Fujita Y, Iki M, Yura A, Miura M, Sato Y, Okamoto N, Kurumatani N.
   Ratio of Endogenous Secretory Receptor for Advanced Glycation End Products to Pentosidine Predicts Fractures in Men.
   J Clin Endocrinol Metab. 1;103(1):85-94,2018.
3. Kouda K, Ohara K, Fujita Y, Nakamura H, Tachiki T, Iki M.
   Relationships between serum leptin levels and bone mineral parameters in school-aged children: a 3-year follow-up study.
   J Bone Miner Metab. 2018 Feb 2. doi: 10.1007/s00774-018-0909-0. [Epub ahead of print]

ゲノム生物学教室（西尾　和人　教授）

1. Oiso N, Sakai K, Nishio K, Kawada A.
   Phylloid hypomelanosis associated with a mosaic trisomy 13 in the 13q31.3-qter region: atypical phylloid distribution and typical hypomelanosis.
   Pigment Cell Melanoma Res.,30(2),269-272,2017.
2. Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
   Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.
   Int J Behav Med.,24(4),535-541,2017.
3. Ota K, Tong KI, Goto K, Tomida S, Komuro A, Wang Z, Nishio K, Okada H.
   The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner.
   PLoS One.,12(3),e0173713,2017.
   
4. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.
   Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
   Ann Oncol.,28(7),1532-1539,2017.
5. Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S.
   Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
   Oncotarget,8(24),38717-38730,2017.
6. Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
   Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.
   BMC Cancer,17(1),281,2017.
7. Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.
   Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
   Int J Oncol,50(6),2049-2058,2017.
8. Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A.
   Incidence of carnitine deficiency in patients with cancer pain: A pilot study.
   Mol Clin Oncol,6(3),331-333,2017.
9. Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.
   A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
   Clin Lung Cancer,18(6),719-723,2017.
10. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.
    DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
    Int J Cancer,141(8),1682-1689,2017.
11. Sakai K, Ukita M, Schmidt J, Wu L, De Velasco MA, Roter A, Jevons L, Nishio K, Mandai M.
    Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
    Cancer Lett, 1;405,22-28,2017.
12. Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I.
    Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
    Int J Hematol,106(5),691-703,2017.
13. Udo E, Furusato B, Sakai K, Prentice LM, Tanaka T, Kitamura Y, Tsuchiya T, Yamasaki N, Nagayasu T, Nishio K, Fukuoka J.
    Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation.
    Diagn Pathol,12(1),62,2017.
14. Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
    Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.
    Biomed Rep,7(4),380-384, 2017.
15. Oiso N, Sakai K, Narita T, Yanagihara S, Nishio K, Kawada A.
    Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1.
    J Dermatol,45(1),e5-e6,2018.
16. Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.
    Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
    BMC Cancer,17(1),674, 2017.
17. Murakami Y, Sonoda K, Abe H, Watari K, Kusakabe D, Azuma K, Kawahara A, Akiba J, Oneyama C, Pachter JA, Sakai K, Nishio K, Kuwano M, Ono M.
    The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.
    Oncotarget ,8(41),70736-70751,2017.
18. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.
    B7-H3 negatively modulates CTL-mediated cancer immunity.
    Clinical Cancer Research, 1;24(11):2653-2664,2018.